Challenges in the diagnosis and treatment of mucormycosis
Top Cited Papers
Open Access
- 10 March 2018
- journal article
- review article
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 56 (suppl_1), S93-S101
- https://doi.org/10.1093/mmy/myx101
Abstract
The diagnosis and treatment of mucormycosis are challenging. The incidence of the disease seems to be increasing. Hematological malignancies are the most common underlying disease in countries with high income and uncontrolled diabetes in developing countries. Clinical approach to diagnosis lacks sensitivity and specificity. Radiologically, multiple (≥10) nodules and pleural effusion are reportedly associated with pulmonary mucormycosis. Another finding on computerized tomography (CT) scan, which seems to indicate the presence of mucormycosis, is the reverse halo sign. Microscopy (direct and on histopathology) and culture are the cornerstones of diagnosis. Molecular assays can be used either for detection or identification of mucormycetes, and they can be recommended as valuable add-on tools that complement conventional diagnostic procedures. Successful management of mucormycosis is based on a multimodal approach, including reversal or discontinuation of underlying predisposing factors, early administration of active antifungal agents at optimal doses, complete removal of all infected tissues, and use of various adjunctive therapies. Our armamentarium of antifungals is slightly enriched by the addition of two newer azoles (posaconazole and isavuconazole) to liposomal amphotericin B, which remains the drug of choice for the initial antifungal treatment, according to the recently published guidelines by ECIL-6, as well as those published by ECMM/ESCMID. Despite the efforts for better understanding of the pathogenesis, early diagnosis and aggressive treatment of mucormycosis, the mortality rate of the disease remains high.Keywords
This publication has 93 references indexed in Scilit:
- Mortality in Hematologic Malignancy and Hematopoietic Stem Cell Transplant Patients with Mucormycosis, 2001 to 2009Antimicrobial Agents and Chemotherapy, 2011
- The Deferasirox–AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trialJournal of Antimicrobial Chemotherapy, 2011
- Mucormycosis Caused by Unusual Mucormycetes, Non-Rhizopus, -Mucor, and -Lichtheimia SpeciesClinical Microbiology Reviews, 2011
- Correlation between In Vitro Activity of Posaconazole and In Vivo Efficacy against Rhizopus oryzae Infection in MiceAntimicrobial Agents and Chemotherapy, 2010
- Safety and Outcomes of Open-Label Deferasirox Iron Chelation Therapy for MucormycosisAntimicrobial Agents and Chemotherapy, 2009
- Activity of Posaconazole and Other Antifungal Agents against Mucorales Strains Identified by Sequencing of Internal Transcribed SpacersAntimicrobial Agents and Chemotherapy, 2009
- In Vitro Activity of Isavuconazole against Aspergillus Species and Zygomycetes According to the Methodology of the European Committee on Antimicrobial Susceptibility TestingAntimicrobial Agents and Chemotherapy, 2009
- Combination Polyene‐Caspofungin Treatment of Rhino‐Orbital‐Cerebral MucormycosisClinical Infectious Diseases, 2008
- Zygomycetes Hyphae Trigger an Early, Robust Proinflammatory Response in Human Polymorphonuclear Neutrophils through Toll-Like Receptor 2 Induction but Display Relative Resistance to Oxidative DamageAntimicrobial Agents and Chemotherapy, 2008
- In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal AgentsAntimicrobial Agents and Chemotherapy, 2007